Advertisement

Active Surveillance for Low-Risk Non-Muscle Invasive Bladder Cancer

  • Rodolfo Hurle
  • Carmen Maccagnano
  • Giovanni Forni
Chapter

Abstract

Active Surveillance (AS) is an accepted policy in several low-risk malignancies, such as prostate cancer, small renal tumours, and in clinical stage I seminomatous germ cell tumours.

Regarding Bladder Cancer (BC), Non-Muscle Invasive Bladder Cancer (NMIBC) accounts for ~50% of newly diagnosed cancers; although an high percentage of local recurrence has been reported in literature, only a small number of patients will progress to Muscle Invasive Bladder Cancer (MIBC). In this context, AS might be a reasonable strategy in patients presenting with small low-grade pTa/pT1a recurrent papillary BC, with acceptable risks of stage and grade progression. Recently the mid-term results from the BIAS (BIAS: Bladder cancer Italian Active Surveillance) Project, whose primary outcome was the check of adherence to AS its self have been published.

Keywords

Active surveillance Low-risk non-muscle invasive bladder cancer 

References

  1. 1.
    Hardie C, Parker C, Norman A, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005;95:956–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU Int. 2015;115:216–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Yang G, Villalta JD, Meng MV, Whitson JM. Evolving practice patterns for the management of small renal masses in the USA. BJU Int. 2012;110:1156–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Lazzeri M, Guazzoni G. Early 21st Century renal cell carcinoma: a “paradigm shift”. Cancer. 2010;116:3080–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Heidenreich A. Clinical stage I nonseminomatous testicular germ-cell tumours: surgery or watchful waiting, still an issue? Curr Opin Urol. 2002;12:427–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Millan-Rodrıguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164:680–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170:438–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Rieken M, Xylinas E, Kluth L, et al. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol. 2014;65:201–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Martinez Caceres P, Hidalgo Arroyo JG, Chechile Toniolo GE. Is it necessary to always treat the relapses of superficial bladder tumour at the moment of diagnosis? Preliminary communication. Actas Urol Esp. 2005;29:567–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Gofrit ON, Shapiro A. Active surveillance of low grade bladder tumors. Arch Ital Urol Androl. 2008;80(4):132–5.PubMedGoogle Scholar
  12. 12.
    Pruthi RS, Baldwin N, Bhalani V, Wallen EM. Conservative management of low risk superficial bladder tumors. J Urol. 2008;179:87–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Hernandez V, Alvarez M, de la Peña E, et al. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology. 2009;73:1306–10.CrossRefPubMedGoogle Scholar
  14. 14.
    De la Pena E, Hernandez V, Blazquez C, Perez E, Diaz FJ, Llorente C. Oncological safety of an active surveillance program in recurrent non muscle-invasive bladder tumour. J Urol. 2013;189(Suppl):e731.CrossRefGoogle Scholar
  15. 15.
    Lozano F, Raventos C, Orsola A, et al. Active surveillance in low risk bladder cancer when TUR is recommended? J Urol. 2014;191(Suppl):e569.CrossRefGoogle Scholar
  16. 16.
    Hernández V, Llorente C, de la Peña E, Pérez-Fernández E, Guijarro A, Sola I. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016;34(4):165.e19–23.CrossRefGoogle Scholar
  17. 17.
    Hurle R, Pasini L, Lazzeri M, Colombo P, Buffi N, Lughezzani G, et al. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project. BJU Int. 2016;118(6):935–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Rodolfo Hurle
    • 1
  • Carmen Maccagnano
    • 2
  • Giovanni Forni
    • 3
  1. 1.Department of UrologyIstituto Clinico Humanitas IRCCS, Clinical and Research HospitalMilanItaly
  2. 2.Division of Urology, Department of SurgeryASST Lariana, Sant’Anna HospitalComoItaly
  3. 3.Humanitas UniversityMilanItaly

Personalised recommendations